Development of prohibitin ligands against osteoporosis - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue European Journal of Medicinal Chemistry Année : 2020

Development of prohibitin ligands against osteoporosis

Résumé

Current therapeutic approaches to osteoporosis display some potential adverse effects and a limited efficacy on non-vertebral fracture reduction. Some sulfonylamidines targeting the scaffold proteins prohibitins-1 and 2 (PHB1/2) have been showed to inhibit the formation of osteoclasts in charge of bone resorption. Herein, we report the development of a second generation of anti-osteoclastic PHB ligands. The most potent compound, IN45, showed 88% inhibition at the low concentration of 5 μM, indicates that it might serve as a basis for the development of new antiosteoporotic drugs.

Domaines

Chimie

Dates et versions

hal-03004271 , version 1 (13-11-2020)

Identifiants

Citer

Redouane Tabti, François Lamoureux, Céline Charrier, Benjamin Ory, Dominique Heymann, et al.. Development of prohibitin ligands against osteoporosis. European Journal of Medicinal Chemistry, 2020, pp.112961. ⟨10.1016/j.ejmech.2020.112961⟩. ⟨hal-03004271⟩
39 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More